<i>IDH1/2</i>but not<i>DNMT3A</i>mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

Houria Debarri, Claude Preudhomme, Shéhérazade Sebda et al.|Oncotarget|2015

Cited by 98